144 related articles for article (PubMed ID: 38250137)
1. Dupilumab Reduces Asthma Disease Burden and Recurrent SCS Use in Patients with CRSwNP and Coexisting Asthma.
Gurnell M; Radwan A; Bachert C; Lugogo N; Cho SH; Nash S; Zhang H; Khan AH; Jacob-Nara JA; Rowe PJ; Deniz Y
J Asthma Allergy; 2024; 17():1-8. PubMed ID: 38250137
[TBL] [Abstract][Full Text] [Related]
2. Dupilumab Improves Outcomes in Patients with Chronic Rhinosinusitis with Nasal Polyps and Coexisting Asthma Irrespective of Baseline Asthma Characteristics.
Busse WW; Pavord ID; Siddiqui S; Khan AH; Praestgaard A; Nash S; Jacob-Nara JA; Rowe PJ; Deniz Y
J Asthma Allergy; 2023; 16():411-419. PubMed ID: 37096015
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
[TBL] [Abstract][Full Text] [Related]
4. Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma.
Laidlaw TM; Bachert C; Amin N; Desrosiers M; Hellings PW; Mullol J; Maspero JF; Gevaert P; Zhang M; Mao X; Khan AH; Kamat S; Patel N; Graham NMH; Ruddy M; Staudinger H; Mannent LP
Ann Allergy Asthma Immunol; 2021 May; 126(5):584-592.e1. PubMed ID: 33465455
[TBL] [Abstract][Full Text] [Related]
5. Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP.
Desrosiers M; Mannent LP; Amin N; Canonica GW; Hellings PW; Gevaert P; Mullol J; Lee SE; Fujieda S; Han JK; Hopkins C; Fokkens W; Jankowski R; Cho SH; Mao X; Zhang M; Rice MS; Khan AH; Kamat S; Patel N; Graham NMH; Ruddy M; Bachert C
Rhinology; 2021 Jun; 59(3):301-311. PubMed ID: 33847325
[TBL] [Abstract][Full Text] [Related]
6. Clinical Efficacy among Patients with Chronic Rhinosinusitis with Nasal Polyps and Clinical Features of Obstructive Lung Disease: Post Hoc Analysis of the Phase III SINUS-24 and SINUS-52 Studies.
Maspero JF; Bachert C; Martinez FJ; Hanania NA; Ortiz B; Patel N; Mannent LP; Praestgaard A; Pandit-Abid N; Siddiqui S; Hardin M
J Asthma Allergy; 2023; 16():333-342. PubMed ID: 37026112
[TBL] [Abstract][Full Text] [Related]
7. Dupilumab efficacy in patients with chronic rhinosinusitis with nasal polyps with and without allergic rhinitis.
Peters AT; Wagenmann M; Bernstein JA; Khan AH; Nash S; Jacob-Nara JA; Siddiqui S; Rowe PJ; Deniz Y
Allergy Asthma Proc; 2023 Jul; 44(4):265-274. PubMed ID: 37480206
[No Abstract] [Full Text] [Related]
8. Dupilumab provides early and durable improvement of symptoms in patients with chronic rhinosinusitis with nasal polyps.
Gevaert P; Lee SE; Settipane RA; Wagenmann M; Msihid J; Siddiqui S; Nash S; Jacob-Nara JA; Khan AH; Kamat S; Chuang CC
Clin Transl Immunology; 2023; 12(1):e1433. PubMed ID: 36721661
[TBL] [Abstract][Full Text] [Related]
9. Dupilumab improves health related quality of life: Results from the phase 3 SINUS studies.
Lee SE; Hopkins C; Mullol J; Msihid J; Guillemin I; Amin N; Mannent LP; Li Y; Siddiqui S; Chuang CC; Kamat S; Khan AH
Allergy; 2022 Jul; 77(7):2211-2221. PubMed ID: 35034364
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS-24 and SINUS-52.
Bachert C; Khan AH; Lee SE; Hopkins C; Peters AT; Fokkens W; Praestgaard A; Radwan A; Nash S; Jacob-Nara JA; Deniz Y; Rowe PJ
Int Forum Allergy Rhinol; 2024 Mar; 14(3):668-678. PubMed ID: 37548085
[TBL] [Abstract][Full Text] [Related]
11. Respiratory Infections and Anti-Infective Medication Use From Phase 3 Dupilumab Respiratory Studies.
Geng B; Bachert C; Busse WW; Gevaert P; Lee SE; Niederman MS; Chen Z; Lu X; Khokhar FA; Kapoor U; Pandit-Abid N; Jacob-Nara JA; Rowe PJ; Deniz Y; Ortiz B
J Allergy Clin Immunol Pract; 2022 Mar; 10(3):732-741. PubMed ID: 34954123
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials.
Mullol J; Laidlaw TM; Bachert C; Mannent LP; Canonica GW; Han JK; Maspero JF; Picado C; Daizadeh N; Ortiz B; Li Y; Ruddy M; Laws E; Amin N
Allergy; 2022 Apr; 77(4):1231-1244. PubMed ID: 34459002
[TBL] [Abstract][Full Text] [Related]
13. Dupilumab improves outcomes in patients with chronic rhinosinusitis with nasal polyps irrespective of gender: results from the SINUS-52 trial.
Fokkens WJ; Bachert C; Hopkins C; Marglani O; Praestgaard A; Nash S; Deniz Y; Rowe PJ; Sacks H; Jacob-Nara JA
Clin Transl Immunology; 2024; 13(6):e1511. PubMed ID: 38854740
[TBL] [Abstract][Full Text] [Related]
14. Rapid and Continuing Improvements in Nasal Symptoms with Dupilumab in Patients with Severe CRSwNP.
Bachert C; Khan AH; Hopkins C; Blaiss MS; Soler ZM; Nash S; Siddiqui S; Praestgaard A; Deniz Y; Rowe PJ; Jacob-Nara JA
J Asthma Allergy; 2022; 15():557-563. PubMed ID: 35548056
[TBL] [Abstract][Full Text] [Related]
15. Effect of Dupilumab on Type 2 Biomarkers in Chronic Rhinosinusitis With Nasal Polyps: SINUS-52 Study Results.
Bachert C; Laidlaw TM; Cho SH; Mullol J; Swanson BN; Naimi S; Classe M; Harel S; Jagerschmidt A; Laws E; Ruddy M; Praestgaard A; Amin N; Mannent LP
Ann Otol Rhinol Laryngol; 2023 Dec; 132(12):1649-1661. PubMed ID: 37322842
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps.
Hopkins C; Wagenmann M; Bachert C; Desrosiers M; Han JK; Hellings PW; Lee SE; Msihid J; Radwan A; Rowe P; Amin N; Deniz Y; Ortiz B; Mannent LP; Rout R
Int Forum Allergy Rhinol; 2021 Jul; 11(7):1087-1101. PubMed ID: 33611847
[TBL] [Abstract][Full Text] [Related]
17. Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal Polyps.
Mullol J; Bachert C; Amin N; Desrosiers M; Hellings PW; Han JK; Jankowski R; Vodicka J; Gevaert P; Daizadeh N; Khan AH; Kamat S; Patel N; Graham NMH; Ruddy M; Staudinger H; Mannent LP
J Allergy Clin Immunol Pract; 2022 Apr; 10(4):1086-1095.e5. PubMed ID: 34628065
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy of dupilumab in asthma with or without chronic rhinosinusitis and nasal polyps.
Berger P; Menzies-Gow A; Peters AT; Kuna P; Rabe KF; Altincatal A; Soler X; Pandit-Abid N; Siddiqui S; Jacob-Nara JA; Deniz Y; Rowe PJ
Ann Allergy Asthma Immunol; 2023 Feb; 130(2):215-224. PubMed ID: 36356712
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design.
De Prado Gomez PharmD MSc L; Khan Mbbs Mph AH; Peters Md AT; Bachert Md PhD C; Wagenmann Md M; Heffler Md PhD E; Hopkins BMBCh C; Hellings Md PhD PW; Zhang PhD M; Xing PhD J; Rowe Md P; Jacob-Nara Md Mph DHSc JA
Am J Rhinol Allergy; 2022 Nov; 36(6):788-795. PubMed ID: 35837739
[TBL] [Abstract][Full Text] [Related]
20. Dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baseline.
Bourdin A; Virchow JC; Papi A; Lugogo NL; Bardin P; Antila M; Halpin DMG; Daizadeh N; Djandji M; Ortiz B; Jacob-Nara JA; Gall R; Deniz Y; Rowe PJ
Respir Med; 2022 Oct; 202():106938. PubMed ID: 36087550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
